NCT04714996招募中2 期
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 4
- 主要终点
- Seizure Frequency
研究概览
简要总结
This is a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study with cross-over to Evaluate the Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double-blind, placebo-controlled
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject/legal guardian must be able to understand and sign the Human Research Ethics Committee-approved written Informed Consent Form (ICF) and privacy language as per national regulations (e.g., HREC and TGA requirement in Australia) prior to any study-related procedures being performed
- •The subject is a male or female 18 to 70 years of age, inclusive
- •The subject must have a history of drug resistant epilepsy (as per the ILAE definition)
- •The subject must be taking 1 to 4 antiepileptic drugs (AED) and must be on a stable dose of the AEDs for at least four (4) weeks prior to entering the 28-day screening period
- •If VNS implanted, the stimulation setting must have been stable for at least four weeks prior to entering the 28-day screening period
- •The subject/legal guardian must be able to use the seizure dairy to record seizure throughout the study
- •The subject must experience at least four (4) countable seizures within a 28-day period.
- •For continued enrollment into Treatment Period 1, each subject will be confirmed to have experienced at least four (4) countable seizures in the 28-day screening period
- •The subject must have interictal epileptiform discharges and/or seizure with an average frequency of at least one (1) per hour on EEG recording.
- •For continued enrollment into Treatment Period 1, this will be confirmed by a 24-hour EEG performed during the 28-day screening period.
- •The subject is willing and able to comply with the study requirements
排除标准
- •Unwilling or inability to follow the procedures specified by the protocol
- •Pregnancy or breast feeding
- •Women of child-bearing potential and men who are unable or unwilling to take adequate contraceptive precautions, including one of the following:
- •Hormonal contraception (birth control pills, injected hormones or vaginal ring) Intrauterine device Barrier methods (condom or diaphragm) combined with spermicideSurgical sterilization (hysterectomy, tubal ligation, or vasectomy)
- •Current treatment for another significant medical disorder, such as diabetes, or heart disease or an untreated disorder, that is discovered during the 28-day screening period and might interfere with the study in the opinion of the Principal Investigator
- •An abnormality on clinical laboratory tests, physical examination, EEG or ECG that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR < 60 mL/min/1.73 m2
- •History (within the month) of illicit drug use or alcohol dependence, and a commitment by the subject to not take the illicit drugs during the study
- •Concomitant treatment with more than four (4) AEDs
- •Evidence for a potentially progressive neurologic disorder, such as a brain tumor, multiple sclerosis or dementia
- •Planned epilepsy surgery within six months of enrollment
研究组 & 干预措施
ES-481
Experimental
干预措施: ES-481 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Open-Label Extension Study
Other
干预措施: Open-Label Extension Study (Drug)
结局指标
主要结局
Seizure Frequency
时间窗: Continuous and at Days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70
A change in seizure frequency and activity assessed using a patient diary and continuous 24-hour EEG monitoring (composite outcome)
次要结局
- Hamilton Anxiety Rating Scale (HAM-A)(Collected at screening, Days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70)
- Hamilton Depression Rating Scale (HDRS)(Collected at screening, Days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70)
- Pharmacokinetics (PK) - AUC0-t(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Laboratory Assessments - Hematology(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Adverse Events(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Laboratory Assessments - Chemistry(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Pharmacokinetics (PK) - Cmax(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Pharmacokinetics (PK) - Tmax(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Pharmacokinetics (PK) - CL/F(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Pharmacokinetics (PK) - AUC0-inf. T1/2(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
- Pharmacokinetics (PK) - Vz/F(Collected at screening, Days 1, 8, 15 22, 28, 43, 50, 57, 64 and 70)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's DiseaseMild Cognitive ImpairmentDementiaNCT05104463CuraSen Therapeutics, Inc.64
已完成
2 期
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic AsthmaAsthmaNCT01501942AIM Therapeutics Inc.11
撤回
2 期
A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)Freezing of Gait Symptoms in Parkinson's DiseaseNCT04935762CuraSen Therapeutics, Inc.
终止
2 期
INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASDAgitation in Adolescents and Young Adults With ASDNCT05163717Impel Pharmaceuticals8
已完成
2 期
Study to Evaluate the Safety and Efficacy of CAT-354AsthmaNCT00873860MedImmune LLC357